{"ok":true,"entry":{"slug":"vilanterol","kind":"medication","name":"vilanterol","aliases":["Relvar"],"brands_sg":["Relvar Ellipta","Anoro Ellipta","Trelegy Ellipta"],"class":"long-acting beta-2 agonist","tags":["respiratory"],"use_for":"regular asthma or copd control, never on its own","use_after":"sg label: one inhalation once daily, same time each day","use_duration":null,"take_with":"an inhaled steroid · sg registers no vilanterol-only inhaler","pros":["sg label: once-daily dosing, morning or evening","sg label: relvar 100/25 is the strength used in copd","us label: a reliever still covers between-dose symptoms"],"cons":["us label: laba alone raises asthma-death risk","us label: not for relief of acute bronchospasm","us label: tremor and heart effects follow beta-2 dosing"],"dose_note":"every label read puts the ceiling at 25 micrograms of vilanterol once daily; only the partner steroid dose changes. the singapore trelegy ellipta label says 'The maximum recommended dosage is 1 inhalation of Trelegy Ellipta 200/62.5/25 mcg once daily' and 'Do not use Trelegy Ellipta more than 1 time every 24 hours'. the us breo ellipta label says 'The maximum recommended dosage is 1 inhalation of BREO ELLIPTA 200/25 mcg once daily'. the us anoro ellipta label says 'Do not use ANORO ELLIPTA more than 1 time every 24 hours'. the singapore relvar label adds that for moderate or severe hepatic impairment 'the maximum dose is 100/25 micrograms'. the prescriber sets the strength.","dosage":null,"ul_status":null,"sg_class":"prescription-only","cautions":["asthma without an inhaled steroid — us label: contraindicated","heart rhythm or other cardiovascular disorders (us label)","convulsive disorders, thyrotoxicosis or diabetes (us label)","severe milk-protein allergy — us label: contraindicated (lactose powder)"],"clashes":[{"src":["fda_breo_warn"],"note":"us label: not to be combined, because of the risk of overdose","with":"another laba-containing inhaler"},{"src":["fda_breo_int"],"note":"us label: raises vilanterol exposure; cardiovascular effects","with":"ketoconazole and other strong cyp3a4 inhibitors"},{"src":["fda_breo_int"],"note":"us label: extreme caution; cardiovascular effects may be potentiated","with":"maois, tricyclic antidepressants and qtc-prolonging drugs"},{"src":["fda_breo_int"],"note":"us label: may block the effect and produce severe bronchospasm","with":"beta-blockers"},{"src":["fda_breo_int"],"note":"us label: ecg changes or hypokalaemia can be acutely worsened","with":"non-potassium-sparing diuretics"}],"sources":[{"id":"hsa_register","url":"https://data.gov.sg/datasets/d_767279312753558cbf19d48344577084/view","label":"HSA — Listing of Registered Therapeutic Products (data.gov.sg open dataset, 5,511 rows, cached in full and filtered locally)","quote":"All 5 vilanterol rows read 'Prescription Only' and every one is a fixed combination — RELVAR ELLIPTA 100/25 and 200/25 (with fluticasone furoate) · ANORO ELLIPTA 62.5/25 (with umeclidinium) · TRELEGY ELLIPTA 100/62.5/25 and 200/62.5/25","accessed":"2026-08-27"},{"id":"ndf_relvar","url":"https://www.ndf.gov.sg/about-drugs/product-information/SIN14736P","label":"National Drug Formulary (SG, MOH) — RELVAR ELLIPTA INHALATION POWDER 100MCG/25MCG [SIN14736P], indications and dosing, last updated 28 Jul 2026","quote":"indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta 2-agonist and inhaled corticosteroid) is appropriate … administered once daily either morning or evening","accessed":"2026-08-27"},{"id":"ndf_trelegy","url":"https://www.ndf.gov.sg/about-drugs/product-information/SIN15806P","label":"National Drug Formulary (SG, MOH) — TRELEGY ELLIPTA INHALATION POWDER 100/62.5/25 MCG [SIN15806P], Dosage and Administration","quote":"The maximum recommended dosage is 1 inhalation of Trelegy Ellipta 200/62.5/25 mcg once daily … Trelegy Ellipta should be used at the same time every day. Do not use Trelegy Ellipta more than 1 time every 24 hours.","accessed":"2026-08-27"},{"id":"fda_breo_ind","url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22BREO+ELLIPTA%22&limit=1","label":"US FDA label — BREO ELLIPTA (fluticasone furoate and vilanterol, GSK), section 1 Indications and Usage, via openFDA (effective 7 Nov 2024)","quote":"a combination of fluticasone furoate, a corticosteroid, and vilanterol, a long-acting beta2-adrenergic agonist (LABA) … Limitations of Use: Not indicated for relief of acute bronchospasm","accessed":"2026-08-27"},{"id":"fda_breo_dose","url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22BREO+ELLIPTA%22&limit=1","label":"US FDA label — BREO ELLIPTA, section 2 Dosage and Administration, via openFDA","quote":"The maximum recommended dosage is 1 inhalation of BREO ELLIPTA 200/25 mcg once daily … If shortness of breath occurs in the period between doses, an inhaled, short-acting beta2-agonist (rescue medicine, e.g., albuterol) should be used","accessed":"2026-08-27"},{"id":"fda_breo_warn","url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22BREO+ELLIPTA%22&limit=1","label":"US FDA label — BREO ELLIPTA, section 5 Warnings and Precautions, via openFDA","quote":"LABA monotherapy increases the risk of serious asthma-related events … Do not use in combination with additional therapy containing a LABA because of risk of overdose … Use with caution in patients with cardiovascular disorders because of beta-adrenergic stimulation","accessed":"2026-08-27"},{"id":"fda_breo_int","url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22BREO+ELLIPTA%22&limit=1","label":"US FDA label — BREO ELLIPTA, section 7 Drug Interactions, via openFDA","quote":"Strong cytochrome P450 3A4 inhibitors (e.g., ketoconazole): Use with caution … Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution … Beta-blockers: … may block bronchodilatory effects … Diuretics: … hypokalemia … may worsen","accessed":"2026-08-27"},{"id":"fda_anoro_dose","url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22ANORO+ELLIPTA%22&limit=1","label":"US FDA label — ANORO ELLIPTA (umeclidinium and vilanterol, GSK), section 2 Dosage and Administration, via openFDA (effective 2 Jun 2023)","quote":"The recommended dosage of ANORO ELLIPTA for maintenance treatment of COPD is 62.5 mcg umeclidinium and 25 mcg vilanterol … once daily by oral inhalation … Do not use ANORO ELLIPTA more than 1 time every 24 hours.","accessed":"2026-08-27"},{"id":"fda_anoro_contra","url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22ANORO+ELLIPTA%22&limit=1","label":"US FDA label — ANORO ELLIPTA, section 4 Contraindications, via openFDA","quote":"use of a long-acting beta2-adrenergic agonist (LABA), including vilanterol … without an inhaled corticosteroid (ICS), in patients with asthma … Severe hypersensitivity to milk proteins or any ingredients … Not indicated for the treatment of asthma","accessed":"2026-08-27"}],"brand_certs":null,"updated_at":"2026-08-29T16:16:34.039038+08:00"},"disclaimer":"kozen-x is not a medical device and does not give medical advice. it lists what published sources have written down. absence of a record is not the same as safe."}